Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against Fusarium Species Ocular Isolates.

Rees CA, Bao R, Zegans ME, Cramer RA.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02505-18. doi: 10.1128/AAC.02505-18. Print 2019 Jul.

PMID:
31010869
2.

Portable Autorefractors for Detecting Axial Length Changes in Space.

Masterova KS, Anderson AP, Cowan DR, Fellows AM, Zegans ME, Buckey JC.

Aerosp Med Hum Perform. 2018 Aug 1;89(8):724-730. doi: 10.3357/AMHP.5049.2018.

PMID:
30020057
3.

Microbial Analysis of Donor Corneoscleral Rims and Storage Media.

Tsui E, Luong PM, Fogel J, Fogel ES, Zegans ME.

Ocul Immunol Inflamm. 2019;27(5):817-820. doi: 10.1080/09273948.2018.1459734. Epub 2018 May 3.

PMID:
29723082
4.

The Significance of Repeat Cultures in the Treatment of Severe Fungal Keratitis.

Ray KJ, Prajna NV, Lalitha P, Rajaraman R, Krishnan T, Patel S, Das M, Shah R, Dhakhwa K, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Rose-Nussbaumer J; Mycotic Ulcer Treatment Trial Group.

Am J Ophthalmol. 2018 May;189:41-46. doi: 10.1016/j.ajo.2018.02.003. Epub 2018 Feb 10.

5.

Thrombospondin-1 protects against pathogen-induced lung injury by limiting extracellular matrix proteolysis.

Qu Y, Olonisakin T, Bain W, Zupetic J, Brown R, Hulver M, Xiong Z, Tejero J, Shanks RM, Bomberger JM, Cooper VS, Zegans ME, Ryu H, Han J, Pilewski J, Ray A, Cheng Z, Ray P, Lee JS.

JCI Insight. 2018 Feb 8;3(3). pii: 96914. doi: 10.1172/jci.insight.96914. eCollection 2018 Feb 8.

6.

Vision Loss Associated With the Opioid Epidemic.

Luong PM, Tsui E, Batra N, Chapman CB, Zegans ME.

JAMA Ophthalmol. 2017 Dec 1;135(12):1449-1451. doi: 10.1001/jamaophthalmol.2017.4868. No abstract available.

7.

Predictors of Corneal Perforation or Need for Therapeutic Keratoplasty in Severe Fungal Keratitis: A Secondary Analysis of the Mycotic Ulcer Treatment Trial II.

Prajna NV, Krishnan T, Rajaraman R, Patel S, Shah R, Srinivasan M, Das M, Ray KJ, Oldenburg CE, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Rose-Nussbaumer J; Mycotic Ulcer Treatment Trial Group.

JAMA Ophthalmol. 2017 Sep 1;135(9):987-991. doi: 10.1001/jamaophthalmol.2017.2914.

8.

Ocular changes over 60 min in supine and prone postures.

Anderson AP, Babu G, Swan JG, Phillips SD, Knaus DA, Toutain-Kidd CM, Zegans ME, Fellows AM, Gui J, Buckey JC.

J Appl Physiol (1985). 2017 Aug 1;123(2):415-423. doi: 10.1152/japplphysiol.00687.2016. Epub 2017 May 25.

9.

Rhodotorula Endogenous Endophthalmitis: A Novel Harbinger of the Injection Drug Epidemic in the United States.

Luong PM, Kalpakian B, Jaeger LJ, Lahey T, Chapman CB, Zegans ME.

Case Rep Infect Dis. 2017;2017:9686353. doi: 10.1155/2017/9686353. Epub 2017 Apr 5.

10.

Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.

Prajna NV, Krishnan T, Rajaraman R, Patel S, Shah R, Srinivasan M, Devi L, Das M, Ray KJ, O'Brien KS, Oldenburg CE, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Rose-Nussbaumer J; Mycotic Ulcer Treatment Trial Group.

JAMA Ophthalmol. 2017 Jun 1;135(6):520-525. doi: 10.1001/jamaophthalmol.2017.0616.

11.

The cif Virulence Factor Gene Is Present in Isolates From Patients With Pseudomonas aeruginosa Keratitis.

Bahl CD, St Laurent JD, Karthikeyan RS, Priya JL, Prajna L, Zegans ME, Madden DR.

Cornea. 2017 Mar;36(3):358-362. doi: 10.1097/ICO.0000000000001132.

12.

Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial.

Prajna NV, Krishnan T, Rajaraman R, Patel S, Srinivasan M, Das M, Ray KJ, O'Brien KS, Oldenburg CE, McLeod SD, Zegans ME, Porco TC, Acharya NR, Lietman TM, Rose-Nussbaumer J; Mycotic Ulcer Treatment Trial II Group.

JAMA Ophthalmol. 2016 Dec 1;134(12):1365-1372. doi: 10.1001/jamaophthalmol.2016.4096.

13.

Aspergillus fumigatus Photobiology Illuminates the Marked Heterogeneity between Isolates.

Fuller KK, Cramer RA, Zegans ME, Dunlap JC, Loros JJ.

MBio. 2016 Sep 20;7(5). pii: e01517-16. doi: 10.1128/mBio.01517-16.

14.

Environmentally Endemic Pseudomonas aeruginosa Strains with Mutations in lasR Are Associated with Increased Disease Severity in Corneal Ulcers.

Hammond JH, Hebert WP, Naimie A, Ray K, Van Gelder RD, DiGiandomenico A, Lalitha P, Srinivasan M, Acharya NR, Lietman T, Hogan DA, Zegans ME.

mSphere. 2016 Sep 7;1(5). pii: e00140-16. doi: 10.1128/mSphere.00140-16. eCollection 2016 Sep-Oct.

15.

Bacterial corneal ulcer associated with common variable immune deficiency.

Tsui E, Deng J, Siedlecki AN, Zegans ME.

J Ophthalmic Inflamm Infect. 2016 Dec;6(1):28. doi: 10.1186/s12348-016-0098-8. Epub 2016 Aug 5.

16.

Candida Interface Infections After Descemet Stripping Automated Endothelial Keratoplasty.

Tsui E, Fogel E, Hansen K, Talbot EA, Tammer R, Fogel J, Daly ER, Noble J, Caine L, Zegans ME.

Cornea. 2016 Apr;35(4):456-64. doi: 10.1097/ICO.0000000000000778.

PMID:
26890665
17.

Surgery Versus Interferon Alpha-2b Treatment Strategies for Ocular Surface Squamous Neoplasia: A Literature-Based Decision Analysis.

Siedlecki AN, Tapp S, Tosteson AN, Larson RJ, Karp CL, Lietman T, Zegans ME.

Cornea. 2016 May;35(5):613-8. doi: 10.1097/ICO.0000000000000766.

18.

Association of Biofilm Formation, Psl Exopolysaccharide Expression, and Clinical Outcomes in Pseudomonas aeruginosa Keratitis: Analysis of Isolates in the Steroids for Corneal Ulcers Trial.

Zegans ME, DiGiandomenico A, Ray K, Naimie A, Keller AE, Stover CK, Lalitha P, Srinivasan M, Acharya NR, Lietman TM.

JAMA Ophthalmol. 2016 Apr;134(4):383-9. doi: 10.1001/jamaophthalmol.2015.5956.

PMID:
26846404
19.

Acute effects of changes to the gravitational vector on the eye.

Anderson AP, Swan JG, Phillips SD, Knaus DA, Kattamis NT, Toutain-Kidd CM, Zegans ME, Fellows AM, Buckey JC.

J Appl Physiol (1985). 2016 Apr 15;120(8):939-46. doi: 10.1152/japplphysiol.00730.2015. Epub 2015 Dec 10.

20.

Unencapsulated Streptococcus pneumoniae from conjunctivitis encode variant traits and belong to a distinct phylogenetic cluster.

Valentino MD, McGuire AM, Rosch JW, Bispo PJ, Burnham C, Sanfilippo CM, Carter RA, Zegans ME, Beall B, Earl AM, Tuomanen EI, Morris TW, Haas W, Gilmore MS.

Nat Commun. 2014 Nov 12;5:5411. doi: 10.1038/ncomms6411.

21.

Considerations in understanding the ocular surface microbiome.

Zegans ME, Van Gelder RN.

Am J Ophthalmol. 2014 Sep;158(3):420-2. doi: 10.1016/j.ajo.2014.06.014. No abstract available.

22.

Early addition of topical corticosteroids in the treatment of bacterial keratitis.

Ray KJ, Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Glidden DV, Oldenburg CE, Sun CQ, Zegans ME, McLeod SD, Acharya NR, Lietman TM.

JAMA Ophthalmol. 2014 Jun;132(6):737-41. doi: 10.1001/jamaophthalmol.2014.292.

23.

Visual recovery in treated bacterial keratitis.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Ray KJ, Zegans ME, Acharya NR, Lietman TM, Keenan JD; Steroids for Corneal Ulcers Trial Group.

Ophthalmology. 2014 Jun;121(6):1310-1. doi: 10.1016/j.ophtha.2013.12.041. Epub 2014 Mar 5. No abstract available.

24.

Evaluation of fungal keratitis using a newly developed computer program, Optscore, for grading digital corneal photographs.

Toutain-Kidd CM, Porco TC, Kidd EM, Srinivasan M, Prajna NV, Acharya N, Lietman T, Zegans ME.

Ophthalmic Epidemiol. 2014 Feb;21(1):24-32. doi: 10.3109/09286586.2013.868003.

25.

Question: Can you identify this condition? Acute retinal necrosis.

Ford JR, Tsui E, Lahey T, Zegans ME.

Can Fam Physician. 2013 Dec;59(12):1307; 1308-10. No abstract available.

26.

The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O'Brien KS, Glidden DV, Ray KJ, Oldenburg CE, Zegans ME, Whitcher JP, McLeod SD, Porco TC, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Am J Ophthalmol. 2014 Feb;157(2):327-333.e3. doi: 10.1016/j.ajo.2013.09.025. Epub 2013 Oct 1.

27.

Subgroup analysis in the steroids for corneal ulcers trial-reply.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Glidden D, Oldenburg CE, Whitcher JP, Zegans ME, McLeod SD, Lietman TM, Acharya NR, Steroids For Corneal Ulcers Trial Group FT.

Arch Ophthalmol. 2012 Jun;130(6):807-8. doi: 10.1001/archophthalmol.2012.352. No abstract available.

28.

The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.

Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group.

JAMA Ophthalmol. 2013 Apr;131(4):422-9.

29.

Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.

Oldenburg CE, Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Borkar DS, Ray KJ, Zegans ME, McLeod SD, Porco TC, Lietman TM, Acharya NR.

Ophthalmic Epidemiol. 2013 Jun;20(3):155-8. doi: 10.3109/09286586.2013.790978. Epub 2013 May 10.

30.

Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis.

Borkar DS, Fleiszig SM, Leong C, Lalitha P, Srinivasan M, Ghanekar AA, Tam C, Li WY, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

JAMA Ophthalmol. 2013 Feb;131(2):147-53. doi: 10.1001/jamaophthalmol.2013.778.

31.

Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial.

See CW, Srinivasan M, Saravanan S, Oldenburg CE, Esterberg EJ, Ray KJ, Glaser TS, Tu EY, Zegans ME, McLeod SD, Acharya NR, Lietman TM.

Ophthalmic Epidemiol. 2012 Dec;19(6):407-13. doi: 10.3109/09286586.2012.735332.

32.

Ganciclovir gel for cytomegalovirus keratouveitis.

Pavan-Langston D, Welch CL, Zegans ME.

Ophthalmology. 2012 Nov;119(11):2411. doi: 10.1016/j.ophtha.2012.07.024. No abstract available.

PMID:
23122464
33.

Nocardia keratitis: clinical course and effect of corticosteroids.

Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Priya JL, Sy A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.

34.

Predictors of outcome in fungal keratitis.

Prajna NV, Krishnan T, Mascarenhas J, Srinivasan M, Oldenburg CE, Toutain-Kidd CM, Sy A, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Porco TC.

Eye (Lond). 2012 Sep;26(9):1226-31. doi: 10.1038/eye.2012.99. Epub 2012 Jun 29.

35.

Pseudomonas aeruginosa exopolysaccharide Psl promotes resistance to the biofilm inhibitor polysorbate 80.

Zegans ME, Wozniak D, Griffin E, Toutain-Kidd CM, Hammond JH, Garfoot A, Lam JS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4112-22. doi: 10.1128/AAC.00373-12. Epub 2012 May 14.

36.

Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, Ravindran M, Cevallos V, Oldenburg CE, Ray KJ, Toutain-Kidd CM, Glidden DV, Zegans ME, McLeod SD, Acharya NR, Lietman TM.

Clin Infect Dis. 2012 May;54(10):1381-7. doi: 10.1093/cid/cis189. Epub 2012 Mar 23.

37.

Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.

Lalitha P, Prajna NV, Oldenburg CE, Srinivasan M, Krishnan T, Mascarenhas J, Vaitilingam CM, McLeod SD, Zegans ME, Porco TC, Acharya NR, Lietman TM.

Cornea. 2012 Jun;31(6):662-7. doi: 10.1097/ICO.0b013e31823f8ae0.

38.

Diphosphonium ionic liquids as broad-spectrum antimicrobial agents.

O'Toole GA, Wathier M, Zegans ME, Shanks RM, Kowalski R, Grinstaff MW.

Cornea. 2012 Jul;31(7):810-6. doi: 10.1097/ICO.0b013e31823f0a86.

39.

Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.

Sy A, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, Oldenburg CE, Ray KJ, Glidden D, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):267-72. doi: 10.1167/iovs.11-7840.

40.

Practice patterns and opinions in the treatment of acanthamoeba keratitis.

Oldenburg CE, Acharya NR, Tu EY, Zegans ME, Mannis MJ, Gaynor BD, Whitcher JP, Lietman TM, Keenan JD.

Cornea. 2011 Dec;30(12):1363-8. doi: 10.1097/ICO.0b013e31820f7763.

41.

Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.

42.

The steroids for corneal ulcers trial: study design and baseline characteristics.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.

43.

Pre-existing blindness in a cohort of patients with bacterial keratitis.

Oldenburg CE, Sy A, Srinivasan M, Toutain-Kidd CM, Mascarenhas J, Ravindran M, Rajaraman R, Esterberg EJ, Chidambaram JD, Acharya NR, Lietman TM, Zegans ME.

Br J Ophthalmol. 2011 Nov;95(11):1612-3. doi: 10.1136/bjophthalmol-2011-300270. Epub 2011 Jun 7. No abstract available.

44.

Clinical signs in dematiaceous and hyaline fungal keratitis.

Oldenburg CE, Prajna VN, Prajna L, Krishnan T, Mascarenhas J, Vaitilingam CM, Srinivasan M, See CW, Cevallos V, Zegans ME, Acharya NR, Lietman TM.

Br J Ophthalmol. 2011 May;95(5):750-1. doi: 10.1136/bjo.2010.198648. Epub 2011 Feb 11. No abstract available.

45.

Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates.

Cady KC, White AS, Hammond JH, Abendroth MD, Karthikeyan RS, Lalitha P, Zegans ME, O'Toole GA.

Microbiology. 2011 Feb;157(2):430-437. doi: 10.1099/mic.0.045732-0.

PMID:
28206903
46.

Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates.

Cady KC, White AS, Hammond JH, Abendroth MD, Karthikeyan RS, Lalitha P, Zegans ME, O'Toole GA.

Microbiology. 2011 Feb;157(Pt 2):430-7. doi: 10.1099/mic.0.045732-0. Epub 2010 Nov 16.

47.

Comparison of natamycin and voriconazole for the treatment of fungal keratitis.

Prajna NV, Mascarenhas J, Krishnan T, Reddy PR, Prajna L, Srinivasan M, Vaitilingam CM, Hong KC, Lee SM, McLeod SD, Zegans ME, Porco TC, Lietman TM, Acharya NR.

Arch Ophthalmol. 2010 Jun;128(6):672-8. doi: 10.1001/archophthalmol.2010.102.

48.

Corynebacterium macginleyi isolated from a corneal ulcer.

Ruoff KL, Toutain-Kidd CM, Srinivasan M, Lalitha P, Acharya NR, Zegans ME, Schwartzman JD.

Infect Dis Rep. 2010 Feb 17;2(1). pii: 1568.

49.

Clinical features, outcomes, and costs of a conjunctivitis outbreak caused by the ST448 strain of Streptococcus pneumoniae.

Zegans ME, Sanchez PA, Likosky DS, Allar RT, Martin M, Schwartzman JD, Pryor JH, Turco JH, Whitney CG.

Cornea. 2009 Jun;28(5):503-9. doi: 10.1097/ICO.0b013e3181909362.

50.

Polysorbate 80 inhibition of Pseudomonas aeruginosa biofilm formation and its cleavage by the secreted lipase LipA.

Toutain-Kidd CM, Kadivar SC, Bramante CT, Bobin SA, Zegans ME.

Antimicrob Agents Chemother. 2009 Jan;53(1):136-45. doi: 10.1128/AAC.00500-08. Epub 2008 Oct 27.

Supplemental Content

Loading ...
Support Center